CoChat

Proteomics Analysis of Human Skeletal Muscle Reveals Novel Abnormalities in Obesity and Type 2 Diabetes

Open access
Hwang, Hyonson, Bowen, Benjamin P., Lefort, Natalie, Flynn, Charles R., De Filippis, Elena A., Roberts, Christine, Smoke, Christopher C., Meyer, Christian, Højlund, Kurt, Yi, Zhengping, Mandarino, Lawrence J. · 2010 · Diabetes

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Insulin resistance in skeletal muscle is an early phenomenon in the pathogenesis of type 2 diabetes. Studies of insulin resistance usually are highly focused. However, approaches that give a more global picture of abnormalities in insulin resistance are useful in pointing out new directions for research. In previous studies, gene expression analyses show a coordinated pattern of reduction in nuclear-encoded mitochondrial gene expression in insulin resistance. However, changes in mRNA levels may not predict changes in protein abundance. An approach to identify global protein abundance changes involving the use of proteomics was used here. RESEARCH DESIGN AND METHODS: Muscle biopsies were obtained basally from lean, obese, and type 2 diabetic volunteers (n = 8 each); glucose clamps were used to assess insulin sensitivity. Muscle protein was subjected to mass spectrometry–based quantification using normalized spectral abundance factors. RESULTS: Of 1,218 proteins assigned, 400 were present in at least half of all subjects. Of these, 92 were altered by a factor of 2 in insulin resistance, and of those, 15 were significantly increased or decreased by ANOVA (P < 0.05). Analysis of protein sets revealed patterns of decreased abundance in mitochondrial proteins and altered abundance of proteins involved with cytoskeletal structure (desmin and alpha actinin-2 both decreased), chaperone function (TCP-1 subunits increased), and proteasome subunits (increased). CONCLUSIONS: The results confirm the reduction in mitochondrial proteins in insulin-resistant muscle and suggest that changes in muscle structure, protein degradation, and folding also characterize insulin resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-0214

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Work flow of statistical analysis of single proteins.
FIG. 1. Work flow of statistical analysis of single proteins.CC BY-NC-ND · PubMed Central
FIG. 2. Work flow of statistical analysis of protein sets.
FIG. 2. Work flow of statistical analysis of protein sets.CC BY-NC-ND · PubMed Central
FIG. 3. Linearity of the relationships between spectral abundance factors observed when 30 and 120 μg protein were analyzed, as described in research design and methods. Similar data obtained for 30 vs. 60 and 60 vs. 120 μg protein loading were compared (data not shown).
FIG. 3. Linearity of the relationships between spectral abundance factors observed when 30 and 120 μg protein were analyzed, as described in research design and methods. Similar data obtained for 30 vs. 60 and 60 vs. 120 μg protein loading were compared (data not shown).CC BY-NC-ND · PubMed Central
FIG. 4. Relative changes in abundance in mitochondrial proteins (A), cytoskeletal and structural proteins (B), TCP1 (chaperonin) complex proteins (C), and proteins involved in proteolytic process or protein modification leading to degradation (D). Data are given as means ± SE NSAF values for lean control (□), obese nondiabetic (), and type 2 diabetic participants (■). All NSAF values were multiplied by 10,000 for purposes of presentation. *P < 0.05, **P < 0.01 vs. lean control subjects (see research design and methods for details). All proteins shown were different among groups by ANOVA (at least P < 0.05) or differed by at least a factor of 2 among at least two groups. Numbers in parentheses as follows indicate the number of subjects with that protein assigned (non–zero-NSAF) for lean, obese, and diabetic subjects, respectively: COX6C, cytochrome c oxidase subunit 6c (7, 8, 7); UQCRQ, ubiquinol-cytochrome C reductase complex ubiquinone-binding protein QP-C (6, 2, 4); CHCHD3, coiled-coil helix coiled-coil helix domain containing protein 3 (8, 7, 4); TCP1, T-complex protein 1 delta (7, 7, 8), theta (7, 7, 8), alpha (6, 6, 7), eta (2, 4, 6); Beta 3, proteasome subunit beta type 3 (4, 4, 6); Alpha 2, proteasome subunit alpha type 2 (4, 8, 7); 26S reg. 3, 26S proteasome regulatory subunit 3 (4, 3, 6); 26S reg. 4, 26S proteasome regulatory subunit 4 (3, 6, 4); Beta 4, proteasome subunit beta type 4 (4, 6, 6); 26S sub. 11, 26S proteasome subunit 11 (4, 6, 7); 26S reg. 7, 26S regulatory subunit 7 (5, 5, 7).
FIG. 4. Relative changes in abundance in mitochondrial proteins (A), cytoskeletal and structural proteins (B), TCP1 (chaperonin) complex proteins (C), and proteins involved in proteolytic process or protein modification leading to degradation (D). Data are given as means ± SE NSAF values for lean control (□), obese nondiabetic (), and type 2 diabetic participants (■). All NSAF values were multiplied by 10,000 for purposes of presentation. *P < 0.05, **P < 0.01 vs. lean control subjects (see research design and methods for details). All proteins shown were different among groups by ANOVA (at least P < 0.05) or differed by at least a factor of 2 among at least two groups. Numbers in parentheses as follows indicate the number of subjects with that protein assigned (non–zero-NSAF) for lean, obese, and diabetic subjects, respectively: COX6C, cytochrome c oxidase subunit 6c (7, 8, 7); UQCRQ, ubiquinol-cytochrome C reductase complex ubiquinone-binding protein QP-C (6, 2, 4); CHCHD3, coiled-coil helix coiled-coil helix domain containing protein 3 (8, 7, 4); TCP1, T-complex protein 1 delta (7, 7, 8), theta (7, 7, 8), alpha (6, 6, 7), eta (2, 4, 6); Beta 3, proteasome subunit beta type 3 (4, 4, 6); Alpha 2, proteasome subunit alpha type 2 (4, 8, 7); 26S reg. 3, 26S proteasome regulatory subunit 3 (4, 3, 6); 26S reg. 4, 26S proteasome regulatory subunit 4 (3, 6, 4); Beta 4, proteasome subunit beta type 4 (4, 6, 6); 26S sub. 11, 26S proteasome subunit 11 (4, 6, 7); 26S reg. 7, 26S regulatory subunit 7 (5, 5, 7).CC BY-NC-ND · PubMed Central
FIG. 5. Results of analysis of manually curated protein sets for complexes I–V of the electron transport chain (ETC). Data are given as means ± SE scaled NSAF values for lean control (□), obese nondiabetic (), and type 2 diabetic participants (■). *P < 0.05, **P < 0.01 vs. lean control subjects (see research design and methods for details).
FIG. 5. Results of analysis of manually curated protein sets for complexes I–V of the electron transport chain (ETC). Data are given as means ± SE scaled NSAF values for lean control (□), obese nondiabetic (), and type 2 diabetic participants (■). *P < 0.05, **P < 0.01 vs. lean control subjects (see research design and methods for details).CC BY-NC-ND · PubMed Central
FIG. 6. Heat maps clustering proteins into groups with similar abundance relative to a global median, obtained using the program GEDI. A total of 400 proteins with spectra obtained in at least 12 of 24 subjects were analyzed. Proteins assigned by the GEDI algorithm to areas 1–7 are given in supplemental Table 5. Proteins were grouped based on their pattern of changes relative to a global median, where shades of blue indicate proteins decreased relative to overall median, green indicates little change, and shades of yellow, orange, and red indicate proteins with increased abundance relative to the global median. GEDI maps cluster proteins into “neighborhoods” with other proteins that display similar patterns of changes among the groups; axes are unit-less. (A high-quality color digital representation of this figure is available in the online issue.)
FIG. 6. Heat maps clustering proteins into groups with similar abundance relative to a global median, obtained using the program GEDI. A total of 400 proteins with spectra obtained in at least 12 of 24 subjects were analyzed. Proteins assigned by the GEDI algorithm to areas 1–7 are given in supplemental Table 5. Proteins were grouped based on their pattern of changes relative to a global median, where shades of blue indicate proteins decreased relative to overall median, green indicates little change, and shades of yellow, orange, and red indicate proteins with increased abundance relative to the global median. GEDI maps cluster proteins into “neighborhoods” with other proteins that display similar patterns of changes among the groups; axes are unit-less. (A high-quality color digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 7. Immunoblot analysis comparing abundance of desmin (A) and alpha actinin-2 (B) content in skeletal muscle biopsies from lean (□), obese nondiabetic (), and type 2 diabetic (■) (n = 7 each). Density values from blots were expressed relative to PDLIM6 protein determined on the same blots and were normalized for each protein to the mean value of the lean controls, expressed as 100%. Representative blots from lean, obese, and diabetic subjects (two of each) are shown in the inset for both proteins. Data are shown as means ± SE. *P < 0.05 vs. lean control values.
FIG. 7. Immunoblot analysis comparing abundance of desmin (A) and alpha actinin-2 (B) content in skeletal muscle biopsies from lean (□), obese nondiabetic (), and type 2 diabetic (■) (n = 7 each). Density values from blots were expressed relative to PDLIM6 protein determined on the same blots and were normalized for each protein to the mean value of the lean controls, expressed as 100%. Representative blots from lean, obese, and diabetic subjects (two of each) are shown in the inset for both proteins. Data are shown as means ± SE. *P < 0.05 vs. lean control values.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 261

Metadata

Authors
Hwang, H., Bowen, B. P., Lefort, N., Flynn, C. R., De Filippis, E. A., Roberts, C., Smoke, C. C., Meyer, C., Højlund, K., Yi, Z., & Mandarino, L. J.
Affiliations
  • Arizona State University (US)
  • Center for Metabolic Biology, Arizona State University, Tempe, Arizona;
  • Odense University Hospital (DK)
Corresponding author
Mandarino, Lawrence J.
Venue
Diabetes
Published
2009-10-15
Volume
59
Issue
1
Pages
33-42
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2160330411
Cited by
255
References
53
Citations by year
2026: 6 · 2025: 11 · 2024: 7 · 2023: 17 · 2022: 9 · 2021: 18 · 2020: 15 · 2019: 16 · 2018: 21 · 2017: 20 · 2016: 18 · 2015: 15 · 2014: 22 · 2013: 20 · 2012: 11
FWCI
5.37
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
Funders
  • American Diabetes Association
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081750, R01-DK-66483, R01DK047936, R01DK066483, R01-DK-47936)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
skeletal muscle, insulin resistance, type 2 diabetes, obesity, muscle proteome, mitochondrial proteins, desmin, ACTN2, molecular chaperones, proteasome, protein degradation, protein folding, insulin sensitivity
MeSH terms
Adult, Biopsy, Cytoskeletal Proteins, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Mitochondria, Muscle, Obesity, Peptide Hydrolases, Reference Values, Mass Spectrometry, Glucose Clamp Technique, Body Mass Index, Muscle, Skeletal, Chaperonins, Gene Expression Profiling, Proteomics, Chaperonin Containing TCP-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.